As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...

Eli Lilly (NYSE: LLY) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...

Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...

Eli Lilly is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid ...

Kellanova (NYSE:K) shares are trading relatively flat on Thursday. The company reported fourth quarter adjusted earnings per share of 92 cents, beating the street view of 83 cents. Quarterly sales of ...

NEW YORK: Wall Street stocks climbed early Thursday, digesting mixed earnings from big US companies ahead of key employment market data. Weekly US jobless claims inched higher in a move analysts said ...

Investing.com - Eli Lilly’s (NYSE: LLY) full-year profit forecast largely surpassed Wall Street expectations on Thursday, as ...

Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of ...